Meeting
2013 ASCO Annual Meeting
Correlation between VEGF and VEGF-R polymorphisms, toxicity, and clinical outcome in HCC patients receiving sorafenib.
Authors
Luca Faloppi
Department of Medical Oncology - Università Politecnica delle Marche, Ancona, Italy
Luca Faloppi , Mario Scartozzi , Maristella Bianconi , Cristian Loretelli , Gianluca Svegliati Baroni , Samuele De Minicis , Alessandra Mandolesi , Riccardo Giampieri , Alessandro Bittoni , Michela Del Prete , Elena Maccaroni , Luca Cecchini , Italo Bearzi , Antonio Benedetti , Stefano Cascinu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4123)
DOI
10.1200/jco.2013.31.15_suppl.4123
Abstract #
4123
Poster Bd #
29A
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.
First Author: Luca Faloppi
Poster
2016 Gastrointestinal Cancers Symposium
Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study.
First Author: Luca Faloppi
Poster
2020 ASCO Virtual Scientific Program
An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.
First Author: Rohini Sharma
Poster
2018 ASCO Annual Meeting
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
First Author: Lynn G. Feun